Meeting
2020 ASCO Virtual Scientific Program
Comprehensive genomic profiling of 216 Chinese patients with renal cell carcinoma.
Authors
Congwang Zhang
GloriousMed Technology Co., Ltd., Shanghai, China
Congwang Zhang , Chunhe Yang , Jie Chen , Xiaohong Xu , Lingyu Wang , Rongbo Lin , Yining Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3532)
DOI
10.1200/JCO.2020.38.15_suppl.3532
Abstract #
3532
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.
First Author: Gennady Bratslavsky
Poster
2022 ASCO Annual Meeting
Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.
First Author: Gennady Bratslavsky
Poster
2020 ASCO Virtual Scientific Program
Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.
First Author: Gennady Bratslavsky
Poster
2020 Genitourinary Cancers Symposium
NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.
First Author: Evgeny Yakirevich